Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen, Arash Pakseresht, Sue D. Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A. Wadden, Ildiko Lingvay
Topics & Concepts
SemaglutideMedicinePlaceboOverweightType 2 diabetesInternal medicineBody mass indexDiabetes mellitusRandomized controlled trialGlycated hemoglobinPhysical therapyEndocrinologyLiraglutideAlternative medicinePathologyDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerBariatric Surgery and Outcomes